In addition to the genes listed above, Myriad Genetics MyRisk® Hereditary Cancer Test includes RiskScore®, a precision medicine tool that predicts a woman’s five year and lifetime risk for developing breast cancer. RiskScore analyzes over 100 genetic markers combined with the Tyrer-Cuzick model to estimate a woman’s risk for developing breast cancer.

RiskScore is calculated for women under age 85 without a personal history of breast cancer, LCIS, hyperplasia, atypical hyperplasia, or a breast biopsy with unknown results. RiskScore is not calculated if the patient is known to carry a mutation in a breast cancer risk gene other that CHEK2, or if there are any known mutations in high-penetrance breast cancer risk genes in the patient’s family.

To learn more about RiskScore and the medical management guidelines provided for patients identified to have a remaining lifetime risk of breast cancer >20%, you may view the result insert by clicking the link below.

View RiskScore Insert

Genes selected for MyRisk satisfy these criteria:

  • Cancer Focus
    • Hereditable contribution
    • Association with overlapping syndromes
  • Penetrance
    • Cancer risk is at least 2-3 times the general population
  • Clinically Significant
    • Based on increased cancer risk from societal guidelines or determined by multiple studies
    • Change in management inferred based on risk level

Each gene tested with MyRisk links to one or more of 11 cancer sites:
Breast, Ovarian, Colorectal, Uterine, Skin, Pancreatic, Gastric, Prostate, Renal, Lung, and Endocrine.

MyRisk simplifies the test selection process by providing you the most comprehensive hereditary cancer panel test with clinically significant results. Be confident you are testing for the primary clinically significant genes associated with your patients’ risk.

Myriad's family of products

  • Myrisk™ Hereditary Cancer Test

    Identifies risk of developing 11 hereditary cancers

  • EndoPredict® Breast Cancer Prognostic Test

    Identifies risk of breast cancer recurrence to inform treatment strategies

  • BRACAnalysis CDx® Germline Companion Diagnostic Test

    Identifies BRCA1/2 mutations to inform treatment strategies

  • MyChoice® CDx Myriad HRD Companion Diagnostic Test

    Identifies HRD status to inform treatment strategies

  • Prolaris® Prostate Cancer Prognostic Test

    Identifies prostate cancer aggressiveness to inform treatment strategies

  • Foresight® Carrier Screen

    Identifies at-risk couples for a pregnancy affected by inherited conditions

  • Prequel® Prenatal Screen

    Identifies risk of chromosomal conditions for expectant parents

  • GeneSight® Mental Health Medication Test

    Identifies how genes affect outcomes with certain mental health medications

Previous Test
    Next Test

    2023 Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad MyRisk Hereditary Cancer, the Myriad MyRisk Hereditary Cancer logo, BRACAnalysis, the BRACAnalysis logo, Prolaris, the Prolaris logo, Foresight, the Foresight logo, GeneSight, the GeneSight logo, MyChoice, MyChoice logo, Endopredict, the Endopredict logo, Prequel, the Prequel logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.